Acta is helping to redefine how Alzheimer’s disease is treated and prevented by advancing the breakthrough discoveries of renowned Harvard Medical School-Massachusetts General Hospital neuroscientist and Acta’s scientific founder, Dr. Rudolph E. Tanzi. Acta’s pipeline leverages more than 40 years of Dr. Tanzi’s scientific accomplishments and $70 million in research and corporate funding to create safe, effective therapies that are affordable and accessible. Created in 2022, the Boston-based company is currently investigating GSM-779690T, a next-generation gamma-secretase modulator (GSM) designed for the treatment and potential prevention of Alzheimer’s disease, in clinical studies.
| Website | http://www.actapharmaceuticals.com |
| Employees | 3 (2 on RocketReach) |
| Founded | 2022 |
| Phone | +1 1508243854 |
| Industry | Pharmaceutical Manufacturing |
Looking for a particular Acta Pharmaceuticals employee's phone or email?
George Alex is the CEO of Acta Pharmaceuticals.
2 people are employed at Acta Pharmaceuticals.